Title |
HDL in sepsis – risk factor and therapeutic approach
|
---|---|
Published in |
Frontiers in Pharmacology, October 2015
|
DOI | 10.3389/fphar.2015.00244 |
Pubmed ID | |
Authors |
Emily E. Morin, Ling Guo, Anna Schwendeman, Xiang-An Li |
Abstract |
High-density lipoprotein (HDL) is a key component of circulating blood and plays essential roles in regulation of vascular endothelial function and immunity. Clinical data demonstrate that HDL levels drop by 40-70% in septic patients, which is associated with a poor prognosis. Experimental studies using Apolipoprotein A-I (ApoAI) null mice showed that HDL deficient mice are susceptible to septic death, and overexpressing ApoAI in mice to increase HDL levels protects against septic death. These clinical and animal studies support our hypothesis that a decrease in HDL level is a risk factor for sepsis, and raising circulating HDL levels may provide an efficient therapy for sepsis. In this review, we discuss the roles of HDL in sepsis and summarize the efforts of using synthetic HDL as a potential therapy for sepsis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | 1% |
Unknown | 77 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 12% |
Researcher | 9 | 12% |
Other | 8 | 10% |
Student > Bachelor | 7 | 9% |
Student > Postgraduate | 6 | 8% |
Other | 16 | 21% |
Unknown | 23 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 32% |
Agricultural and Biological Sciences | 8 | 10% |
Biochemistry, Genetics and Molecular Biology | 6 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
Immunology and Microbiology | 3 | 4% |
Other | 7 | 9% |
Unknown | 24 | 31% |